Skip to main content

Advertisement

Table 2 Treatment outcome in patients with uncomplicated falciparum infection treated with dihydroartemisinin–piperaquine (DHA/PPQ) or artemether–lumefantrine (AL) in Bosaso and Jowhar sites, Somalia

From: High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia

Treatment responses DHA-PP AL
Bosaso (N = 92) Jowhar (N = 108) Bosaso (N = 88) Jowhar (N = 51)
Parasitaemia on day 3 0 (0) 0 (0) 0 (0) 0 (0)
PCR-uncorrected
 ETF, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
 LCF, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
 LPF, n (%) 2 (2.5) 3 (2.8) 0 (0) 0 (0)
 ACPR, n (%) 78 (97.5) 103 (97.2) 84 (100) 51 (100)
 Total per protocol 80 106 84 51
 Lost/withdrawn, n (%) 12 (13.0) 2 (1.9) 4 (4.5) 0 (0)
 Kaplan–Meier: cure rate 78 (97.5) 103 (97.2) 84 (100) 51 (100)
PCR-corrected
 ETF, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
 LCF, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
 LPF, n (%) NA* 1 (1.0) 0 (0) 0 (0)
 ACPR, n (%) NA* 103 (99.0) 84 (100) 51 (100)
 Total per protocol NA* 104 84 51
 Lost/withdrawals/re-infection: n (%) NA* 4 (3.7) 4 (4.5) 0 (0)
 Kaplan–Meier: cure rate NA* 103 (99.1) 84 (100) 51 (100)
  1. *PCR analysis to differentiate between recrudescence and new infection was not done for the two patients in the DHA/PPQ group in Bosaso because suitable samples were not available at the time of recurrence
  2. ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response